2017
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
Brown J, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. British Journal Of Cancer 2017, 118: 312-324. PMID: 29123260, PMCID: PMC5808021, DOI: 10.1038/bjc.2017.376.Peer-Reviewed Educational MaterialsConceptsImmunogenic cell deathDNA-damaging therapeuticsPromote immunogenic cell deathPhase I-III trialsDurable response rateDNA-damaging agentsAntitumour immune responseRegimens to patientsProperties of malignant cellsChoice of combinationsCell deathAntitumour immunitySequence of agentsNeoantigen productionTumor microenvironmentMalignant cellsNeoantigen repertoireInflammatory milieuPreclinical workImmune cellsCombination trialsDamaging agentsImmunological memoryMinimal toxicityHypothesis-driven trial
2016
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins D, Sundar R, Lim J, Yap T. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends In Pharmacological Sciences 2016, 38: 25-40. PMID: 27871777, DOI: 10.1016/j.tips.2016.10.012.Peer-Reviewed Educational MaterialsConceptsPrecision medicineNext-generation sequencingMechanisms of drug resistanceField of immunotherapyManagement of cancer patientsOptimize treatment efficacyAntitumor responseIntertumoral heterogeneityClonal evolutionTargeted agentsMinimal toxicityDrug resistanceCancer patientsTreatment efficacyBiomarker developmentBiomarker discoveryCancer researchCancerCompounds promisesImmunotherapyMedicine